The Call for Tender (CfT) will be issued in winter 2021 (1st quadrimester). The CfT will remain open for submission of tenders for at least 60 days. OncNGS CfT shall be open to any interested suppliers, with no need for a special invitation or specific pre-qualification requirements.
Phase 1 suppliers will design their solution based on their background and their analysis of the technology strategy, technical feasibility, quality plan, risks assessment, business model, financial feasibility, ethics and data protection management done to satisfy oncNGS requirements.
Overall duration : 11 months
Phase 2 suppliers will develop their solution and demonstrate their analytical validity having followed the Analytical test plan approved in Phase 1.
Overall duration : 14 months
Phase 3 suppliers will validate their approved analytical solution on the oncNGS and demonstrate the clinical validity of the solution following the protocol approved in Phase 2 and authorized by the relevant ethical committees and all the other authorizing entities/agencies.
Overall duration : 18 months
The oncNGS consortium groups several buyers in 5 EU countries to challenge the market to develop novel affordable solutions to provide the most advanced NGS tests for cancer patients. We wish to co-develop an EU innovative tender for liquid biopsy diagnostics based on complex NGS-driven DNA profiling within a pre-commercial procurement Horizon-2020 financed project.
Latest information about partners, events, ...